Nearly three million people globally live with multiple sclerosis, a chronic disease in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. In the United States alone, close to one million people are living with MS, according to a landmark study that found the figure was more than double what had previously been assumed. Global prevalence rose from about 2.3 million people in 2013 to 2.8 million in 2020, and the number keeps climbing. Despite this growing burden, treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.
Quantum BioPharma (NASDAQ: QNTM) is working to change that with its lead drug candidate, Lucid-MS. The company is pursuing a new path for better multiple sclerosis treatments by designing Lucid-MS to inhibit demyelination directly. The candidate targets an enzyme called peptidyl arginine deiminase 2, a mechanism that distinguishes it from existing therapies that primarily modulate the immune system rather than protect myelin. By focusing on demyelination, Quantum BioPharma aims to address the underlying pathology that leads to nerve damage and disability progression in MS.
The importance of this approach lies in the urgent need for therapies that can slow or halt disease progression, particularly in progressive forms of MS where treatment options are limited. If successful, Lucid-MS could offer a novel way to preserve myelin and potentially improve long-term outcomes for patients. The global MS market is substantial, with significant unmet need driving research and development across the biotechnology sector. Quantum BioPharma’s efforts underscore the growing interest in neuroprotective strategies that go beyond symptom management.
For investors and industry observers, Quantum BioPharma’s progress with Lucid-MS represents a potential breakthrough in a field where innovation has been slow. The company’s focus on a specific enzyme target could pave the way for a new class of MS treatments. As the prevalence of MS continues to rise, the demand for effective therapies will only increase, making Quantum BioPharma’s work particularly noteworthy.
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, provides ongoing coverage of developments like these. As part of the Dynamic Brand Portfolio @ IBN, BioMedWire delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. The platform is uniquely positioned to serve private and public companies seeking to reach a wide audience of investors, influencers, consumers, journalists, and the general public. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. This story is based on a press release issued by BioMedWire and is for informational purposes only.
